Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - An approach using data clustering methods and the internet

European Journal of Cancer

Volumn 43, Issue 1, 2007, Pages 104-113

  Stein, Ken ^a   Sugar, Catherine ^b   Velikova, Galina ^c   Stark, Dan ^d  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

Internet; Ovarian cancer; Preference based measures; Quality of life; Standard gamble; Utility

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DATA ANALYSIS; FEMALE; HEALTH STATUS; HUMAN; INTERNET; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PUBLIC OPINION; QUALITY ADJUSTED LIFE YEAR;

ADULT; AGED; FEMALE; HEALTH STATUS; HUMANS; INTERNET; MIDDLE AGED; OVARIAN NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 33846011080     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.09.007     Document Type: Article

References (33)

1. Cancer Research UK. CancerStatus: ovarian cancer - UK. London, Cancer Research UK; 2004 [Ref. Type: Generic].
2. Velikova G., Booth L., Smith A., Brown P., Lynch P., Brown J., et al. Measuring quality of life in routine oncology practice improves communication and patient well being: a randomized controlled trial. J Clin Oncol 22 4 (2004) 714-724
3. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. National Institute for Clinical Excellence: London; 2004 [Ref Type: Report].
4. Glennie J., Torrance G.W., Baladi J., Berka C., Hubbard E., Menon D., et al. The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics 15 5 (1999) 459-468
5. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., and Russell L.B. recommendations of the panel on cost-effectiveness in health and medicine consensus statement. JAMA 276 15 (1996) 1253-1258
6. Brazier J., Deverill M., Green C., Harper R., and Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 3 9 (1999)
7. Main C., Ginelly L., Griffin S., Norman G., Barbieri M., Mather L., et al. A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer. Health Technol Assess 10 9 (2006)
8. Grann V., Jacobson J., Thomason J., Hershman D., Heitjan D., and Neugut A. Effect of prevention strategies on survival and quality adjusted survival for women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20 10 (2002) 2520-2529
9. Ortega A., Dranitsaris G., Sturgeon J., Sutherland H., and Oza A. Cost utility analysis of pacllitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynaecol Oncol 66 (1997) 454-463
10. Bennett C., Golub R., Calhoun E., Weinstein J., Fishman D., Lurain J., et al. Cost utility assessment of amifostine as first-line therapy for ovarian cancer. Int J Gynaecol Cancer 8 (1998) 64-72
11. Calhoun E., Fishman D., Lurain J., Welshman E., and Bennett C. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population and physicians. Gynaecol Oncol 93 (2004) 164-169
12. Tengs T., and Wallace A. 1000 health-related QOL estimates. Med Care 38 6 (2000) 583-637
13. Tengs T., and Wallace A. 1000 Health-related QOL Estimates. Medical Care 38 6 (2000) 583-637
14. Stalmeier P.F.M., Goldstein M.K., Holmes A.M., and Lenert L. What should be reported in a methods section on utility assessment. Med Decis Making 21 (2001) 200-207
15. Deverill M., Brazier J., Green C., and Booth A. The use of QALY and non-QALY measures of health-related quality of life. Pharmacoeconomics 13 4 (1998) 411-420
16. Froberg D.G., and Kane R.L. Methodology for measuring health-state preferences-III: population and context effects. [Review] [30 refs]. J Clin Epidemiol 42 6 (1989) 585-592
17. Gerard K., Dobson M., and Hall J. Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer. J Clin Epidemiol 46 1 (2001) 77-84
18. Lenert L.A., Cher D.J., Goldstein M.K., Bergen M.R., and Garber A. The effect of search procedures on utility elicitations. Med Decis Making 18 (1998) 76-83
19. Furlong W.J., Feeny D.H., Torrance G.W., and Barr R.D. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 33 (2001) 375-384
20. Kind P, Hardman G, Macran S. UK population norms for EQ-5D, vol. 172. University of York: York. CHE Discussion Paper; 1999 [Ref. Type: Report].
21. Espallargues M., Czoski-Murray C., Bansback N., Carlton J., lewis G., Hughes L., et al. The impact of age related macular degeneration on health state utility values. Invest Ophth Vis Sci 46 11 (2005) 4016-4023
22. Stein K., Fry A., Round A., Milne R., and Brazier J. What value health? A review of health state values used in early technology assessments for NICE. Appl Health Econ Policy (2006)
23. Lenert L.A., Lin A., Olshen R., and Sugar C. Clustering in the service of the public's health. Bull Int Stat Inst 52 1 (1999) 71-74
24. Sugar C., James G., Lenert L., and Rosenheck R. Discrete state analysis for interpretation of data from clinical trials. Med Care 42 (2004) 183-196
25. Schunemann H., Stahl H., Austin P., Akl E., Armstrong D., and Guyatt G. A comparison of narrative and table formats for presenting hypothetical health states to patients with gastrointestinal or pulmonary disease. Med Decis Making 24 (2004) 53-60
26. Lenert L., and Kaplan R.M. Validity and interpretation of preference-based measures of health-related quality of life. Med Care 38 9 (2000) 138-150
27. Rutten-van Molken M., Bakker C., van Doorslaer E., and van der Linden S. Methodological issues of patient utility measurement: experience from two clinical trials. Med Care 33 9 (1995) 922-937
28. Torrance G.W., Boyle M.H., and Horwood S.P. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 30 6 (1982) 1043-1069
29. Dolan P., and Kind P. Inconsistency and health state valuations. Soc Sci Med 42 4 (1996) 609-615
30. Sackett D., and Torrance G. The utility of different health states as perceived by the general public. J Chron Dis 31 (1978) 697-704
31. Brazier J., Deverill M., and Green C. A review of the use of health status measures in economic evaluation. J Health Serv Res Policy 4 3 (1999) 174-184
32. Stalmeier P.F.M., Goldstein M.K., Holmes A.M., Lenert L., Miyamoto J., Stiggelbout A.M., et al. What should be reported in a methods section on utility assessment?. Med Decis Making 21 (2001) 200-207
33. Dolan P. Effect of age on health state valuations. J Health Serv Res Policy 5 1 (2000) 17-21